Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > Last in class
View:
Post by goldtech on Jan 14, 2022 1:15pm

Last in class

They keep saying first in class, but the markets say they are last in class. They have no knowledge about how to promote a public company.
Comment by M101 on Jan 14, 2022 2:35pm
I assume you meant they say best in class, but glib slogans aside, how do you think the company should be properly promoted?  
Comment by goldtech on Jan 14, 2022 3:20pm
First they must actually do a deal and not spout off that a deal is imminent like they have been doing these past 2 plus years. They then have to replace Directors that do nothing like Wyman, Kirwin, Gregory and put together a management team of credible people who have actually succeed in business. The markets don't like the fact that Gene and Elliott are all talk and no results.
Comment by M101 on Jan 14, 2022 4:05pm
Ok but that's not promotion.  If we had a competent ceo who's loyalty was instead to the company and shareholders then they could publicly applaud the CMS first draft, today.  Publishing a thoughtful opinion piece on CMS vs Biogen could go viral given the medicare debate, and this is the only way Promis could afford to get it past corporate media.  He could just put it on ...more  
Comment by DavidKingCanada on Jan 14, 2022 4:14pm
Definitely agree with that M101
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities